bis(tri-n-butyltin)oxide: RN given refers to parent cpd; RN in Chemline for tributylin: 688-73-3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16682746 |
| CHEBI ID | 81543 |
| SCHEMBL ID | 19183 |
| MeSH ID | M0047870 |
| Synonym |
|---|
| hexabutyldistannoxane |
| nsc22332 |
| mykolastanox f |
| nsc-22332 |
| oxybis[tributyltin] |
| kyslicnik tri-n-butylcinicity |
| nsc28132 |
| stannane, oxide |
| c-sn-9 |
| 56-35-9 |
| bis(tri-n-butylzinn)-oxyd |
| lastanox t 20 |
| lastanox f |
| vikol lo-25 |
| wln: 4-sn-4&4&o-sn-4&4&4 |
| bis(tributyltin oxide) |
| distannoxane, hexabutyl- |
| lastanox q |
| nsc-28132 |
| biomet |
| 6-oxa-5, 5,5,7,7-tetrabutyl- |
| l.s. 3394 |
| biomet tbto |
| biomet 66 |
| tbto |
| oxybis(tributylstannane) |
| stannicide a |
| ent 24,979 |
| bis-(tri-n-butylcin)oxid |
| tributyltin oxide |
| vikol af-25 |
| bis(tributyltin) oxide |
| tin, oxybis(tributyl- |
| lastanox t |
| butinox |
| bis(tributylstannyl)oxide |
| biomet srm |
| bis(tri-n-butyltin)oxide, technical grade |
| hexabutyl distannoxane |
| bis(tributylstannium) oxide |
| hexabutyldistannioxan [czech] |
| bis(tri-n-butyltin) oxide |
| ai3-24979 |
| bis(tributyl tin)oxide |
| nsc 22332 |
| bis(tri-n-butylzinn)-oxyd [german] |
| bis-(tri-n-butylcin)oxid [czech] |
| oxyde de tributyletain |
| caswell no. 101 |
| otbe [french] |
| epa pesticide chemical code 083001 |
| zk 21995 |
| einecs 200-268-0 |
| 6-oxa-5,7-distannaundecane, 5,5,7,7-tetrabutyl- |
| bis(tri-n-butyltin)oxide |
| ccris 3697 |
| kyslicnik tri-n-butylcinicity [czech] |
| tin, bis(tributyl)-, oxide |
| oxybis(tributyl tin) |
| stannane, tri-n-butyl-, oxide |
| oxybis(tributyltin) |
| hsdb 6505 |
| bis(tributyloxide) of tin |
| HBD , |
| bis(tributyltin) oxide, 96% |
| NCGC00163942-01 |
| tributyltin oxide (tbto) |
| bis(tributyltin)oxide |
| tributyltin hydrate |
| apqhkwpgghmykj-uhfffaoysa- |
| C18149 |
| chebi:81543 , |
| A831016 |
| tributyl(tributylstannyloxy)stannane |
| NCGC00163942-02 |
| 3353q84mkm , |
| otbe |
| hexabutyldistannioxan |
| unii-3353q84mkm |
| ec 200-268-0 |
| distannoxane, 1,1,1,3,3,3-hexabutyl- |
| NCGC00260546-01 |
| cas-56-35-9 |
| dtxcid10166 |
| tox21_203001 |
| dtxsid9020166 , |
| BP-20397 |
| FT-0623098 |
| AKOS015909709 |
| SCHEMBL19183 |
| bis(tri-n-butylstannyl) oxide |
| (bu3sn)2o |
| tributyltinoxide |
| bis(tributyl stannyl)oxide |
| bis(tri-n-butylstannyl)oxide |
| bis (tri-n-butyltin) oxide |
| hexabutyidistannoxane |
| (nbu3sn)2o |
| tributyltin oxide [hsdb] |
| tributyltin(iv) oxide |
| bis[tri-n-butyltin(iv)]oxide |
| oxybis[tributylstannane] |
| tbot |
| tributyl tin oxide |
| 1,1,1,3,3,3-hexabutyldistannoxane # |
| keycide x-10 (salt/mix) |
| mfcd00009418 |
| tbto, pestanal(r), analytical standard |
| tbto (bis(tributyltin) oxide) |
| Q384794 |
| EN300-219085 |
| tributyl[(tributylstannyl)oxy]stannane |
| tributyltin(iv) oxide; |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In parent quail, neither diminished food consumption nor any overt toxic or histopathologic signs were observed following exposure to TBTO." | ( Subchronic toxicity and reproduction effects of tri-n-butyltin oxide in Japanese quail. Brouwer, A; Coenen, TM; Enninga, IC; Koeman, JH, 1992) | 0.28 |
| "The toxic effects of bis (tributyltin) oxide (TBTO) on the rat liver were studied with an electron microscope and the accumulation sites of tin were determined with an X-ray microanalyzer." | ( Studies on the hepatotoxicity induced by bis (tributyltin) oxide. Doi, Y; Fujimoto, S; Hara, K; Haramaki, N; Kawahara, A; Mori, N; Yokoyama, M; Yoshizuka, M, 1992) | 0.28 |
| "The toxic effects of bis (tributyltin) oxide (TBTO) on the ultrastructure and permeability of rat thoracic aorta were studied electron microscopically and the accumulation sites of tin were determined with an X-ray microanalyzer." | ( The toxic effects of bis (tributyltin) oxide on the rat thoracic aorta. Doi, Y; Fujimoto, S; Hara, K; Mori, N; Ono, E; Yokoyama, M; Yoshizuka, M, 1992) | 0.28 |
| " In a 10-day toxicity study, the LD50 and LD10 were 74 and 34 mg/kg bw, respectively." | ( Evaluation of the genetic and embryotoxic effects of bis(tri-n-butyltin)oxide (TBTO), a broad-spectrum pesticide, in multiple in vivo and in vitro short-term tests. Barale, R; Brun, G; Davis, A; Forster, R; Günther, T; Hautefeuille, H; Knaap, AG; Krowke, R; Kuroki, T; van der Heijden, CA, 1987) | 0.52 |
| "Relative to an industrial application, the authors relate results obtained from a peculiar study on the thermic degradation of bis (tri-n-butyltin) oxide (TBTO) at various temperatures and they account for the toxic effects observed after inhaling the combustion products in the mouse and guinea pig." | ( [Thermal degradation of tributyltin oxide and pulmonary toxicity of its combustion products in mice and guinea pigs]. Anger, F; Anger, JP; Brault, A; Brunet, P; Cano, Y; Louvet, M; Saccavini, JC; Truhaut, R; Van den Driessche, J, 1981) | 0.26 |
| " The inhibition of the protein synthesis and secretion might be caused partly by mitochondrial dysfunctions due to the toxic effects of TBTO." | ( Toxic effects of bis (tributyltin) oxide on the synthesis and secretion of zymogen granules in the rat exocrine pancreas. Fujimoto, S; Hara, K; Yoshizuka, M, 1994) | 0.29 |
| " Mitochondria dysfunction due to the toxic effects of bis (tributyltin) oxide induced changes in the secretory cells of rat sweat glands." | ( Sweat gland toxicity induced by bis (tributyltin) oxide: an ultrastructural and X-ray microanalysis study. Doi, Y; Fujimoto, S; Kudo, H; Yamamoto, O; Yoshizuka, M, 2000) | 0.31 |
| " Although not established absolutely, it is generally believed that development constitutes a period of increased immune system susceptibility to xenobiotics, since adverse effects may occur at lower doses and/or immunomodulation may be more persistent, thus increasing the relative risk of xenobiotic exposure to the immunologically immature organism." | ( The comparative immunotoxicity of five selected compounds following developmental or adult exposure. Chen, DH; Dietert, R; King, M; Luebke, RW; Luster, MI; Yang, Y, ) | 0.13 |
| " These findings suggest that TBTO exerts its toxic effects on the thymus primarily by affecting apoptotic processes, but the possibility is discussed that this may in fact represent an early effect that precedes inhibition of cell proliferation." | ( In vitro immunotoxicity of bis(tri-n-butyltin)oxide (TBTO) studied by toxicogenomics. Arkusz, J; Baken, KA; Pennings, JLA; van Loveren, H; Vandebriel, RJ, 2007) | 0.64 |
| "Xenobiotics may cause long-term adverse effects in humans, especially at the embryonic level, raising questions about their levels of exposure, combined effects, and crucial endpoints." | ( Cytotoxic effects and aromatase inhibition by xenobiotic endocrine disrupters alone and in combination. Benachour, N; Moslemi, S; Seralini, GE; Sipahutar, H, 2007) | 0.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chemical bioavailability in Organisation for Economic Co-operation and Development (OECD) artificial soil can contrast with bioavailability in natural soils and produce ecotoxicologic benchmarks that are not representative of species' exposure conditions in the field." | ( The effect of tributyltin-oxide on earthworms, springtails, and plants in artificial and natural soils. Jänsch, S; Junker, T; Pohl, B; Römbke, J; Schallnass, HJ; Scheffczyk, A, 2007) | 0.34 |
| Class | Description |
|---|---|
| inorganic molecular entity | A molecular entity that contains no carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 1.7439 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 0.4140 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.1438 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 1.0792 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 1.0792 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.2120 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 0.4800 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 2.3792 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 3.7708 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 0.2881 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 0.9724 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 15.7744 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720691; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 0.7128 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 0.8320 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.0485 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259403 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 9.0569 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 0.2379 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 4.6012 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 13.7757 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID588535; AID743212; AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 11.7050 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743140; AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 7.8885 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743223; AID743241 |
| caspase-3 | Homo sapiens (human) | Potency | 2.3792 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 2.6695 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.3122 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.2693 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 1.1980 | 0.1549 | 17.8702 | 43.6557 | AID1346877; AID1346891 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 0.2400 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 0.5373 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 0.2429 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 0.6706 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 29.3969 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 0.6706 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.2670 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 0.3487 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 24.0632 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 0.3771 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 8.2462 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743; AID720552 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 0.3771 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 30 (26.79) | 18.7374 |
| 1990's | 47 (41.96) | 18.2507 |
| 2000's | 19 (16.96) | 29.6817 |
| 2010's | 15 (13.39) | 24.3611 |
| 2020's | 1 (0.89) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (14.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 4 (3.28%) | 6.00% |
| Case Studies | 5 (4.10%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 113 (92.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||